Details of the Drug

General Information of Drug (ID: DM6VM38)

Drug Name

Reserpine

Synonyms

Abesta; Abicol; Adelfan; Adelphin; Alkarau; Alkaserp; Alserin; Apoplon; Apsical; Ascoserp; Ascoserpina; Austrapine; Banasil; Banisil; Benazyl; Bioserpine; Brinderdin; Briserine; Broserpine; Cardioserpin; Carditivo; Carpacil; Carrserp; Darebon; Deserpine; Dralserp; Eberpine; Eberspine; Ebserpine; Elfanex; Elserpine; Enipresser; Escaspere; Eserpine; Eskaserp; Eskaserpine; Gammaserpine; Gilucard; Helfoserpin; Hexaplin; Hiposerpil; Hiserpia; Hydropine; Hydroserp; Hypersil; Hypersine; Hypertensan; Idoserp; Idsoserp; Interpina; Kitine; Klimanosid; Lemiserp; Loweserp; Mallopress; Maviserpin; Mayserpine; Mephaserpin; Modenol; Naquival; Nembuserpin; Neoserfin; Neoserp; Neoslowten; Orthoserpina; Perskleran; Pressimedin; Purserpine; Quiescin; Raucap; Raudiford; Raudixin; Raudixoid; Raugal; Raulen; Rauloydin; Raumorine; Raunervil; Raunorine; Raunova; Raupasil; Raupoid; Raurine; Rausan; Rausedan; Rausedil; Rausedyl; Rauserpin; Rauserpine; Rauserpol; Rausingle; Rautrin; Rauvlid; Rauwasedin; Rauwilid; Rauwiloid; Rauwipur; Rauwita; Rauwoleaf; Rawilid; Recipin; Regroton; Resaltex; Resedrex; Resedril; Reserbal; Resercaps; Resercen; Reserfia; Reserjen; Reserlor; Reserp; Reserpal; Reserpamed; Reserpanca; Reserpene; Reserpex; Reserpidefe; Reserpil; Reserpin; Reserpina; Reserpinum; Reserpka; Reserpoid; Reserpur; Reserutin; Resiatric; Residin; Residine; Resine; Resocalm; Resperin; Resperine; Respital; Restran; Rezerpin; Riserpa; Rivased; Rivasin; Rolserp; Roxel; Roxinoid; Roxynoid; Ryser; Salupres; Sandril; Sandron; Sedaraupin; Sedaraupina; Sederaupin; Sedserp; Seominal; Serfin; Serfolia; Serolfia; Serpalan; Serpaloid; Serpaneurona; Serpanray; Serpasil; Serpasol; Serpate; Serpazil; Serpazol; Serpedin; Serpen; Serpena; Serpentil; Serpentin; Serpentina; Serpicon; Serpil; Serpiloid; Serpilum; Serpine; Serpipur; Serpivate; Serpivite; Serpogen; Serpoid; Serpone; Serpyrit; Sertabs; Sertens; Sertensin; Sertina; Supergan; Tefaserpina; Temposerpine; Tensanyl; Tenserpinie; Tensional; Tensionorme; Tepserpine; Terbolan; Transerpin; Triserpin; Tylandril; Unilord; Unipres; VIXO; Esc aspere; Hydromox R; Hypercal B; Loweser p; Neose rfin; Rau sedyl; Renese R; Rese rpamed; Se rpate; V Serp; VI XO; Diupres 250; Diupres 500; ENT 50146; H 520; Hydropres 25; Hydropres 50; Hydrosine 25; R 0875; Apoplon (TN); Diupres-250; Diupres-500; Diurese-R; Diutensen-R; HYDRO-RESERP; Hydrap-ES; Hydromox-R; Key-serpine; L-Carpserp; Neo-serp; Rau-Sed; Renese-R; Rese-lar; Reser-ar; SK-Reserpine; T-Serp; Usaf cb-27; V-Serp; Vio-Serpine; Cam-Ap-Es; L"-Carpserp; R-e-s; Ser-A-Gen; 3P Reserp

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1], [2]

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

608.7

Topological Polar Surface Area (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Elimination: 1% of drug is excreted from urine in the unchanged form [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.1408 micromolar/kg/day [4]
Water Solubility: The ability of drug to dissolve in water is measured as 0.01 mg/mL [3]

Chemical Identifiers

Formula: C33H40N2O9
IUPAC Name: methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
Canonical SMILES: CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC
InChI: InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1
InChIKey: QEVHRUUCFGRFIF-MDEJGZGSSA-N

Cross-matching ID

PubChem CID: 5770
ChEBI ID: CHEBI:28487
CAS Number: 50-55-5
DrugBank ID: DB00206
TTD ID: D0J4JM
VARIDT ID: DR00636
INTEDE ID: DR2310
ACDINA ID: D00588

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Synaptic vesicle amine transporter (SLC18A2)	TTNZRI3	VMAT2_HUMAN	Blocker	[5]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[6]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Hypertension

ICD Disease Classification

BA00-BA04

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Synaptic vesicle amine transporter (SLC18A2)	DTT	SLC18A2	2.69E-02	-0.04	-0.11
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.39E-02	1.07E-01	2.80E-01
Breast cancer resistance protein (ABCG2)	DTP	BCRP	9.45E-01	-5.34E-02	-9.01E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Reserpine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Moderate	Additive hypertensive effects by the combination of Reserpine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[30]
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Reserpine and Promazine.	Appearance/behaviour symptom [MB23]	[31]
Linezolid	DMGFPU2	Moderate	Additive hypertensive effects by the combination of Reserpine and Linezolid.	Bacterial infection [1A00-1C4Z]	[30]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Reserpine and Cariprazine.	Bipolar disorder [6A60]	[31]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Reserpine due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[32]
Selegiline	DM6034S	Moderate	Additive hypertensive effects by the combination of Reserpine and Selegiline.	Depression [6A70-6A7Z]	[30]
Isocarboxazid	DMAF1NB	Moderate	Additive hypertensive effects by the combination of Reserpine and Isocarboxazid.	Depression [6A70-6A7Z]	[30]
Tranylcypromine	DMGB5RE	Moderate	Additive hypertensive effects by the combination of Reserpine and Tranylcypromine.	Depression [6A70-6A7Z]	[30]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Reserpine and OPC-34712.	Depression [6A70-6A7Z]	[31]
Phenelzine	DMHIDUE	Moderate	Additive hypertensive effects by the combination of Reserpine and Phenelzine.	Depression [6A70-6A7Z]	[30]
Tetrabenazine	DMYWQ0O	Major	Additive antidopaminergic effects by the combination of Reserpine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[33]
Deutetrabenazine	DMUPFLI	Major	Additive antidopaminergic effects by the combination of Reserpine and Deutetrabenazine.	Dystonic disorder [8A02]	[33]
Ripretinib	DM958QB	Moderate	Decreased clearance of Reserpine due to the transporter inhibition by Ripretinib.	Gastrointestinal stromal tumour [2B5B]	[34]
Procarbazine	DMIK367	Moderate	Additive hypertensive effects by the combination of Reserpine and Procarbazine.	Hodgkin lymphoma [2B30]	[30]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Reserpine and Propiomazine.	Insomnia [7A00-7A0Z]	[31]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Reserpine and ITI-007.	Insomnia [7A00-7A0Z]	[31]
Cladribine	DM3JDRP	Moderate	Decreased clearance of Reserpine due to the transporter inhibition by Cladribine.	Mature B-cell leukaemia [2A82]	[34]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Reserpine due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[34]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Reserpine and Thalidomide.	Multiple myeloma [2A83]	[35]
Ozanimod	DMT6AM2	Moderate	Additive hypertensive effects by the combination of Reserpine and Ozanimod.	Multiple sclerosis [8A40]	[30]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Reserpine and Prochlorperazine.	Nausea/vomiting [MD90]	[31]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Reserpine and Promethazine.	Nausea/vomiting [MD90]	[31]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Reserpine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[31]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Reserpine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[31]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Reserpine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[31]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Reserpine and Quetiapine.	Schizophrenia [6A20]	[31]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Reserpine and Mesoridazine.	Schizophrenia [6A20]	[31]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Reserpine and Thioridazine.	Schizophrenia [6A20]	[31]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Reserpine and Aripiprazole.	Schizophrenia [6A20]	[31]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Reserpine and Iloperidone.	Schizophrenia [6A20]	[31]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Reserpine and Paliperidone.	Schizophrenia [6A20]	[31]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Reserpine and Loxapine.	Schizophrenia [6A20]	[31]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Reserpine and Molindone.	Schizophrenia [6A20]	[31]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Reserpine and Chlorpromazine.	Schizophrenia [6A20]	[31]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Reserpine and Thiothixene.	Schizophrenia [6A20]	[31]
Clozapine	DMFC71L	Moderate	Additive hypotensive effects by the combination of Reserpine and Clozapine.	Schizophrenia [6A20]	[31]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Reserpine and Trifluoperazine.	Schizophrenia [6A20]	[31]
Ziprasidone	DMM58JY	Moderate	Additive hypotensive effects by the combination of Reserpine and Ziprasidone.	Schizophrenia [6A20]	[31]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Reserpine and Risperidone.	Schizophrenia [6A20]	[31]
Olanzapine	DMPFN6Y	Moderate	Additive hypotensive effects by the combination of Reserpine and Olanzapine.	Schizophrenia [6A20]	[31]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Reserpine and Amisulpride.	Schizophrenia [6A20]	[31]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Reserpine and Asenapine.	Schizophrenia [6A20]	[31]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Reserpine due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[36]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Reserpine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[31]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Reserpine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[37]
Betrixaban	DM2C4RF	Moderate	Decreased clearance of Reserpine due to the transporter inhibition by Betrixaban.	Venous thromboembolism [BD72]	[38]
-----------


⏷ Show the Full List of 46 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Reserpine 0.25 mg tablet	0.25 mg	Oral Tablet	Oral
Reserpine 0.1 mg tablet	0.1 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4823).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009838.
3	BDDCS applied to over 900 drugs
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8.
6	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
7	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
8	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
9	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
10	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
11	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
12	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
13	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
14	Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
15	Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
16	The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
17	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
18	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
19	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
20	The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
21	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
22	Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
23	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
24	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
25	VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). Prog Med Chem. 2018;57(1):87-111.
26	NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681-7.
27	Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One. 2013 Sep 30;8(9):e75952.
28	Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem. 2011;11(9):1103-27.
29	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
30	De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5. [PMID: 4379192]
31	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
32	Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
33	Product Information. Xenazine (tetrabenazine). Prestwick Pharmaceuticals Inc, Washington DC, VA.
34	Cerner Multum, Inc. "Australian Product Information.".
35	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
36	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
37	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
38	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.